Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Gut. 2022 May 17;72(1):54–65. doi: 10.1136/gutjnl-2022-327471

Figure 1.

Figure 1

Enrolment and allocation of patients and healthy controls in the two study cohorts reported. Note: some patients with Rome III-positive IBS-D participated in both ‘transit’ and ‘colonoscopy’ aims. The numbers of participants with BAD or IBS-D without ABAM are indicated in the two aims of the study. ABAM, abnormal bile acid metabolism; BAD, bile acid diarrhoea; IBS-D, irritable bowel syndrome with diarrhoea; NHV, normal healthy volunteers.